Lithium and GLP-1-based therapies in bipolar disorder: an emerging pharmacovigilance signal and monitoring considerations
{{output}}
Lithium remains a cornerstone of bipolar disorder treatment, yet it has a narrow-therapeutic index and depends on renal and volume status. Glucagon-like peptide-1 (GLP-1) receptor agonists and dual glucose-dependent insulinotropic polypeptide/GLP-1 agonists ar... ...
